Back to News
Market Impact: 0.25
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Source: globenewswire.com
Healthcare & BiotechRegulation & Legislation
The FDA placed the biologics license application for z-rostudirsen for exon 51 Duchenne muscular dystrophy under priority review. The agency’s target action date is January 21, 2027; no approval decision or clinical results were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
More News
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- South Korea’s KOSPI halts trade after 8% wipeout on AI losses
- U.S. stock futures rise after AI rout batters Wall St; payrolls data in focus
- ’Our phones are exploding’: Goldman Sachs dissects historic Wall Street crash
- Top Democrats call to rein in AI buildout after midterms sweep: 'National data center moratorium now'